Steady MedsGHK-Cu
Ordered GHK-Cu from Steady Meds? Mail in a sample (US only) and let us test it.
Test my supplySteady Meds shows a mixed but improving purity-focus record, with recent Sep/Oct Retatrutide and Tirzepatide identity/purity passes offsetting earlier Retatrutide identity failures and Tirzepatide underfill signals. GHK-Cu is similarly uneven, and missing batch IDs or labels limit confidence despite useful recent volume.
We investigated who actually operates Steady Meds — corporate records, ownership trails, web infrastructure, and how its lab results break down product by product. Read the full report before you order.
Unlock original COAs
View and download original lab PDFs for Finnrick tests, including Steady Meds rows.
Cancel anytime
About Steady Meds test results from Finnrick
Steady Meds is a peptide vendor tracked in Finnrick's independent testing dataset. This page compiles batch-level results across 3 peptides and 24 tests, including ratings, observed price signals, recent test dates, and correction history where available.
Finnrick ratings are calculated from published sample data using the selected rating standard. The default standard evaluates purity, dose accuracy, and label quality, then adjusts low-volume results so small sample counts do not appear more certain than the data supports.
The most visible Steady Meds peptides in this dataset are GHK-Cu (6 tests), Retatrutide (11 tests) and Tirzepatide (7 tests). Use the peptide table above to compare the current Finnrick rating, price per mg, and sample volume for each peptide.
Recent tests and corrections are shown below when available. Samples may be acquired by Finnrick directly or submitted through Finnrick testing programs; the goal is to make safety and supply-chain evidence easier to evaluate than vendor marketing claims alone. This page currently lists 24 recent tests.
Ordered GHK-Cu from Steady Meds? Mail in a sample (US only) and let us test it.
Test my supply